WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 314208
CAS#: 320345-99-1
Description: Aclidinium bromide is a long-acting anticholinergic bronchodilator approved by the FDA in 2012 for use in the management of chronic obstructive pulmonary disease (COPD) which includes chronic bronchitis and emphysema. It is not however used for acute exacerbations. Aclidinium bromide is an inhalation powder promoted by Forest Pharmaceuticals in the US under the trade name Tudorza Pressair. It is also manufactured and marketed by Menarini Pharmaceuticals in the EU under the trade name Bretaris Genuair, in the UK as Eklira Genuair and in the Canada as Tudorza Genuair.
MedKoo Cat#: 314208
Name: Aclidinium Bromide
CAS#: 320345-99-1
Chemical Formula: C26H30BrNO4S2
Exact Mass: 563.07996
Molecular Weight: 564.5547
Elemental Analysis: C, 55.31; H, 5.36; Br, 14.15; N, 2.48; O, 11.34; S, 11.36
Synonym: trade name: Eklira Genuair; Tudorza Genuair; Bretaris Genuair
IUPAC/Chemical Name: [(8R)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide
InChi Key: XLAKJQPTOJHYDR-QTQXQZBYSA-M
InChi Code: InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1
SMILES Code: O=C(O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)C(C4=CC=CS4)(O)C5=CC=CS5.[Br-]
Appearance: solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 564.5547 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Woods JA, Nealy KL, Barrons RW. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease. Ann Pharmacother. 2013 Jul-Aug;47(7-8):1017-28. doi: 10.1345/aph.1S002. Epub 2013 Jun 4. Review. PubMed PMID: 23737515.
2: Cazzola M, Page CP, Matera MG. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Jun;14(9):1205-14. doi: 10.1517/14656566.2013.789021. Epub 2013 Apr 9. Review. PubMed PMID: 23566013.
3: Jones P. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv Ther. 2013 Apr;30(4):354-68. doi: 10.1007/s12325-013-0019-2. Epub 2013 Apr 2. Review. PubMed PMID: 23553509.
4: Joos GF. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Drugs Today (Barc). 2012 Dec;48(12):757-63. doi: 10.1358/dot.2012.48.12.1885871. Review. PubMed PMID: 23243632.
5: Gupta V, Singh D. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2012 Dec;6(6):581-8. doi: 10.1586/ers.12.61. Review. PubMed PMID: 23234445.
6: Maltais F, Milot J. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2012 Dec;6(6):345-61. doi: 10.1177/1753465812463626. Epub 2012 Oct 17. Review. PubMed PMID: 23075544.
7: Sims MW, Panettieri RA Jr. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:457-66. doi: 10.2147/COPD.S15524. Epub 2011 Sep 16. Review. PubMed PMID: 22003291; PubMed Central PMCID: PMC3186744.
8: Alagha K, Bourdin A, Tummino C, Chanez P. An update on the efficacy and safety of aclidinium bromide in patients with COPD. Ther Adv Respir Dis. 2011 Feb;5(1):19-28. doi: 10.1177/1753465810381546. Epub 2010 Sep 30. Review. Erratum in: Ther Adv Respir Dis. 2011 Apr;5(2):151. PubMed PMID: 20884687.
9: Sentellas S, Ramos I, Albertà J, Salvà M, Antón F, Miralpeix M, Beleta J, Gavaldà A. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci. 2010 Mar 18;39(5):283-90. doi: 10.1016/j.ejps.2010.01.004. Epub 2010 Jan 20. Review. PubMed PMID: 20093184.
10: Cazzola M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr Opin Investig Drugs. 2009 May;10(5):482-90. Review. PubMed PMID: 19431081.
